vTv Therapeutics Inc.
vTv Therapeutics Inc. (VTVT): 5 pipeline candidates · 2 upcoming catalysts · ~22 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
21.7 months
D/E 0.10
Lead: Phase 3
5 candidates
2 upcoming, next in ~13d
N/A
A transparent, data-derived signal for vTv Therapeutics Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$132.1M
Cash
$98.1M
Quarterly Burn
$13.6M
Runway
21.7 mo
Revenue
$36.8M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| cadisegliatin | Phase 3 |
| cadisegliatin 800 mg bid | Phase 3 |
| cadisegliatin 800 mg qd | Phase 3 |
| hpp3033 | Preclinical |
| ttp273 | Phase 2 |
Upcoming Catalysts (2)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
36.4% historical Phase 2 primary-endpoint success rate (n=228)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
33
Total value held
$51.3M
| Holder | Shares | Value |
|---|---|---|
| samsara biocapital, llc | 298,496 | $11.8M |
| fmr llc | 260,391 | $10.3M |
| vanguard capital management llc | 217,844 | $8.6M |
| millennium management llc | 206,288 | $8.2M |
| baker bros. advisors lp | 148,314 | $5.9M |
| geode capital management, llc | 32,886 | $1.3M |
| northern trust corp | 18,052 | $716K |
| vanguard fiduciary trust co | 16,126 | $640K |
| 683 capital management, llc | 16,000 | $635K |
| marshall wace, llp | 13,389 | $531K |
Showing top 10 of 33 institutional holders of vTv Therapeutics Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in vTv Therapeutics Inc.'s pipeline?
vTv Therapeutics Inc. (VTVT) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is vTv Therapeutics Inc.'s lead drug candidate?
vTv Therapeutics Inc.'s most advanced tracked candidate is cadisegliatin (Phase 3) for Diabetes Mellitus, Type 1; Type 1 Diabetes (T1D).
What is vTv Therapeutics Inc.'s next catalyst?
vTv Therapeutics Inc.'s next tracked catalyst is a Phase2_Start event — "Phase 2 Start: Hybrid CATT1: Hybrid Closed Loop Insulin Pumps With Cadisegliatin as Adjunctive Treatment in Patient" — expected July 1, 2026.
What is vTv Therapeutics Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, vTv Therapeutics Inc. has approximately 21.7 months of cash runway.
What is vTv Therapeutics Inc.'s market capitalization?
vTv Therapeutics Inc.'s market capitalization is approximately $132.1M.
Get the full picture on vTv Therapeutics Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.